The PhaseBio Pharmaceuticals, Inc., PHAS has Gain (↑) on Friday, January 10, 2020 the stock price is settled at $6.79 after buying and selling hours while rehearsed a difference of 20.18 percent. The stock has a fifty two-week low of $165.23 percent while its fifty two-weeks high are $-59.22 percent.
The total market cap for the stock is $210.49M while it has a PE ratio of 0. Active investor focuses on important indicators rehearsed a difference in session that includes where the PhaseBio Pharmaceuticals, Inc..
Each buying and selling session display one-of-a-kind actions and patterns about PhaseBio Pharmaceuticals, Inc. (PHAS) stock. Presently we watched the different factors that seen on close of last session. Toward the day’s end, it’s only a stock’s exhibition that issues.
PhaseBio Pharmaceuticals, Inc.’s overall performance:
The performance of the stock during the last 7.00 days was 28.11 percent,
during the last one-month price index is 104.52 percent while over the 3.00 months is 66.42 percent.
Its 6.00 months performance has been -39.48 percent while for the beyond 52.00 weeks is 87.57 percent.
We have additionally seen that the stock is exchanging 57.92 percent away from the 50-day MA and -15.41 percent of the 20-day MA.
How much shares are traded?
The stock traded hands with 5575558 numbers of shares contrast to its normal every day volume of 397.14K shares.
What amount of stock is unpredictable?
Beta factor was seen at 0. Beta estimates the hazard of the security. High beta >1 means implies higher dangerous and low beta <1 shows low peril. The stock remained 17.15 percent erratic for the ongoing week and 18.25 percent for the last month.
PhaseBio Pharmaceuticals, Inc. has a P/S and P/B values of 110.78 and 2.75 respectively. Its P/Cash valued at 2.57. The PHAS has PEG of 0. Technical indicators do not lead us to assume the stock will see more gains anytime soon.
Analyst’s mean target amount for the company is 20 while analysts mean suggestion is 1.5.